Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Budget In Brief

This article was originally published in The Tan Sheet

Executive Summary

Drug program proposal: FDA requests $1 billion in fiscal 2011 funding for its human drug program, a 13.6 percent increase from the prior-year appropriation, more than half of which would be covered by user fees. The figure presented Feb. 1 in the Obama administration's proposed budget includes $849.7 million for activities within the Center for Drug Evaluation and Research, and $150.5 million for Office of Regulatory Affairs field operations. The agency seeks $446.5 million for new drug review functions across both CDER and ORA. One area of ORA's domestic program - the OTC monograph project and health fraud project inspections - seeks $95 million for fiscal 2011, which would match the 2010 estimate. Of the $1 billion total for drug activities, $516 million is projected to come from user fees - largely those existing under the Prescription Drug User Fee Act. However, $34.4 million in new generic drug user fees and $2.5 million in field re-inspection user fees are proposed for fiscal 2011. The user fee component would represent 51.6 percent of total drug program funding in fiscal 2011, up from 47.2 percent of the 2010 appropriation

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts